Kura Oncology to Participate in Bank of America Securities Healthcare Conference
Kura Oncology (NASDAQ: KURA), a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, has announced its upcoming participation in the Bank of America Securities 2025 Healthcare Conference. The company's President and CEO, Troy Wilson, Ph.D., J.D., will engage in a fireside chat on May 13, 2025, at 6:00 p.m. ET / 3:00 p.m. PT. Investors can access a live audio webcast of the presentation through Kura's website, with a replay available afterward.
Kura Oncology (NASDAQ: KURA), un'azienda biofarmaceutica in fase clinica specializzata in medicine di precisione per il trattamento del cancro, ha annunciato la sua prossima partecipazione alla Bank of America Securities 2025 Healthcare Conference. Il Presidente e CEO dell'azienda, Troy Wilson, Ph.D., J.D., parteciperà a una conversazione informale il 13 maggio 2025 alle 18:00 ET / 15:00 PT. Gli investitori potranno seguire la presentazione in diretta audio streaming tramite il sito web di Kura, con la possibilità di rivedere la registrazione successivamente.
Kura Oncology (NASDAQ: KURA), una empresa biofarmacéutica en etapa clínica enfocada en medicamentos de precisión para el tratamiento del cáncer, ha anunciado su próxima participación en la Conferencia de Salud 2025 de Bank of America Securities. El presidente y CEO de la compañía, Troy Wilson, Ph.D., J.D., participará en una charla informal el 13 de mayo de 2025 a las 6:00 p.m. ET / 3:00 p.m. PT. Los inversores podrán acceder a una transmisión de audio en vivo de la presentación a través del sitio web de Kura, con una repetición disponible posteriormente.
Kura Oncology (NASDAQ: KURA)는 암 치료를 위한 정밀 의약품에 중점을 둔 임상 단계의 바이오제약 회사로, Bank of America Securities 2025 Healthcare Conference에 곧 참여할 예정임을 발표했습니다. 회사의 사장 겸 CEO인 Troy Wilson 박사(Ph.D., J.D.)가 2025년 5월 13일 오후 6시 ET / 오후 3시 PT에 파이어사이드 채팅에 참여할 예정입니다. 투자자들은 Kura 웹사이트를 통해 프레젠테이션의 라이브 오디오 웹캐스트를 시청할 수 있으며, 이후 재방송도 제공됩니다.
Kura Oncology (NASDAQ: KURA), une entreprise biopharmaceutique en phase clinique spécialisée dans les médicaments de précision pour le traitement du cancer, a annoncé sa prochaine participation à la Bank of America Securities 2025 Healthcare Conference. Le président-directeur général de la société, Troy Wilson, Ph.D., J.D., participera à une discussion informelle le 13 mai 2025 à 18h00 ET / 15h00 PT. Les investisseurs pourront accéder à une diffusion audio en direct de la présentation via le site web de Kura, avec une rediffusion disponible par la suite.
Kura Oncology (NASDAQ: KURA), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf Präzisionsmedizin zur Krebsbehandlung spezialisiert hat, hat seine bevorstehende Teilnahme an der Bank of America Securities 2025 Healthcare Conference angekündigt. Der Präsident und CEO des Unternehmens, Troy Wilson, Ph.D., J.D., wird am 13. Mai 2025 um 18:00 Uhr ET / 15:00 Uhr PT an einem Fireside-Chat teilnehmen. Investoren können die Präsentation über einen Live-Audio-Webcast auf der Website von Kura verfolgen, mit der Möglichkeit, die Aufzeichnung anschließend erneut anzusehen.
- None.
- None.
SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2025 Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 6:00 p.m. ET / 3:00 p.m. PT on May 13, 2025. A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with an archived replay following the event.
About Kura Oncology
Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced submission of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at https://kuraoncology.com/ and follow us on X and LinkedIn.
Contacts
Investors:
Patti Bank
Managing Director
(415) 513-1284
patti.bank@icrhealthcare.com
Media:
Alexandra Weingarten
Associate Director, Corporate Communications
& Investor Relations
(858) 500-8822
alexandra@kuraoncology.com
FAQ
When is Kura Oncology (KURA) presenting at the Bank of America Healthcare Conference 2025?
How can investors watch Kura Oncology's (KURA) presentation at the BofA Healthcare Conference?
Who will represent Kura Oncology (KURA) at the 2025 BofA Healthcare Conference?
What type of company is Kura Oncology (KURA)?
